Michael Kubik

Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein

Irving E. Vega, Joseph R. Patterson, C. Kemp, 2022, NPJ Parkinson's disease.

Dopaminergic Positron Emission Tomography Imaging in the Alpha‐Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease

Joseph R. Patterson, V. Sossi, C. Kemp, 2022, Movement disorders : official journal of the Movement Disorder Society.

Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein.

Joseph R. Patterson, C. Kemp, K. Luk, 2021, Parkinsonism & related disorders.

Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein

Irving E. Vega, Joseph R. Patterson, C. Kemp, 2022, npj Parkinson's Disease.

Microglial depletion does not impact alpha-synuclein aggregation or nigrostriatal degeneration in the rat preformed fibril model

Joseph R. Patterson, K. Luk, C. Sortwell, 2023, Research square.

Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils

Joseph R. Patterson, S. Counts, A. Cole-Strauss, 2024, NPJ Parkinson's disease.

Alpha-synuclein inclusion responsive microglia are resistant to CSF1R inhibition

Joseph R. Patterson, C. Sortwell, Matthew J. Benskey, 2024, Journal of neuroinflammation.

Deficits in basal and evoked striatal dopamine release following alpha‐synuclein preformed fibril injection: An in vivo microdialysis study

Joseph R. Patterson, C. Sortwell, Michael Kubik, 2024, The European journal of neuroscience.